- Published at
- by manilatimes.net
positive
positive
News for Adverum Biotechnologies, Inc. (ADVM)
- Published at
- by manilatimes.net
positivepositive- Published at
- by investing.com
positivepositiveADVM stock touches 52-week low at $5.64 amid market challenges By Investing.com
ADVM stock touches 52-week low at $5.64 amid market challenges- Published at
- by gurufocus.com
positivepositiveAdverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. ( ADVM) today announced that on November 17, 2024, the Compensation Comm- Published at
- by manilatimes.net
positivepositive- Published at
- by seekingalpha.com
mixedmixedAdverum: Ixo-Vec Could Reduce Treatment Burden For Wet-AMD Patients (NASDAQ:ADVM)
Adverum Biotechnologies advances wet AMD treatment with promising trial results. See why ADVM stock has potential as it prepares for the ARTEMIS study in 2025.- Published at
- by rttnews.com
positivepositiveAdverum Biotechnologies Reports Positive 52-week Data From LUNA Phase 2 Study; Stock Up
Adverum Biotechnologies, Inc. (ADVM) Monday announced positive topline 52-week data from the LUNA Phase 2 study of the company's gene therapy product candidate Ixo-vec for the treatment of wet AMD.- Published at
- by manilatimes.net
positivepositive- Published at
- by gurufocus.com
positivepositiveAdverum Biotechnologies Announces Positive 52-Week LUNA and 4-Year OPTIC Results, and Provides Key Pivotal Program Design Elements
- 52-week LUNA data combined with follow-up from OPTIC at 4 years continue to support long-term potential best-in-class product profile of Ixo-vec- Published at
- by manilatimes.net
positivepositive- Published at
- by globenewswire.com
mixedmixedAdverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program
REDWOOD CITY, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a company pioneering the use of gene therapy as a...- Published at
- by globenewswire.com
mixedmixedVEGFR-2 Antagonists Clinical Trial Pipeline Insights Featuring 25+ Companies | DelveInsight
VEGFR2 (vascular endothelial growth factor receptor 2) antagonist is an antineoplastic agent that blocks the binding of natural VEGF ligands, which are...- Published at
- by globenewswire.com
mixedmixedRetinal Gene Therapy market is projected to grow at a CAGR of 9.6% by 2034: Visiongain
Visiongain has published a new report entitled Retinal Gene Therapy Market Report 2024-2034: Forecasts by Approach (Gene Replacement, Gene Silencing, Gene...- Published at
- by investing.com
mixedmixedAdverum Biotechnologies reshuffles leadership team By Investing.com
Adverum Biotechnologies reshuffles leadership team- Published at
- by benzinga.com
mixedmixedWhy Lifecore Biomedical Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday’s Mid-Day Session - Lifecore Biomedical (NASDAQ:LFCR)
Shares of Lifecore Biomedical, Inc. (NASDAQ: LFCR) fell sharply during Wednesday’s session after the company announced it concluded its strategic evaluation process, announced management succession and board changes. Lifecore Biomedical shares dipped 31.7% to $4.91 on Wednesday.- Published at
- by seekingalpha.com
mixedmixedVoyager Therapeutics: A Shot At Making Gene Therapy Deliver Easier (NASDAQ:VYGR)
Voyager Therapeutics investors need to be patient as the biotech targets hard to treat Alzheimer's and Parkinson's. Read why the best days are ahead for VYGR stock.VYGR.MXVYGRSRPTSLDBSIGHT.PARGNXPRVLPFED.BAPFECL.SNPFE.SNPFE.MXPFE.DEPFEPASGNVSN.MXNVSEFNVSD.BANVSNOVN.SWN1VS34.SAIONS.MXIONSIDP.DEGSGTFBIIBD.BABIIBCL.SNBIIB.SNBIIB.MXBIIB.BABIIBABBV34.SAABBV.MXABBV.BAABBV4AB.DE0RIM.L0L35.L0K9E.L0JDI.LZEG.DEUQ1.DETSHASGMOQURENBIXLLY.MXLLY.DELLY.BALLYLILY34.SAGBY.DEFOLD.MXFOLDFDMTDUL.DEBMRNAZNN.MXAZNCFAZN.LAZNALNYADVMABEOA1LN34.SA0R1D.L0Q1G.L0K6R.L0HNC.L0HF9.L0HD2.L0HA3.L0H7R.L0EE0.L0A4J.L- Published at
- by globenewswire.com
mixedmixedGene Therapies In Ophthalmology Clinical Trial Pipeline Appears Robust With 55+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
The gene therapies in ophthalmology pipeline and clinical trial analysis report deliver important insights on ongoing research, clinical strategies,...- Published at
- by benzinga.com
mixedmixedWhy Air Products and Chemicals Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Monday’s Mid-Day Session - Adverum Biotechnologies (NASDAQ:ADVM), Air Products & Chemicals (NYSE:
Shares of Air Products and Chemicals, Inc. (NYSE: APD) fell sharply during Monday’s session after the company reported worse-than-expected first-quarter financial results and lowered FY24 adjusted EPS guidance below estimates.YTENXS4.DEWRTCWRAPTSLAD.BATSLAC.BATSLA34.SATSLA.MXTSLATL0.DESANTA.BRSANT.MISAN.MXSAN.MCSAN.BASANON.MXONMPSYFMOR.DEMORLYGJTEVBG.MXEVBGCOINCAMPBSD2.DEBNC.LBCDRFAPD.MXAPDADVM1QZ.DE0KC4.L0HBH.L0HA3.L0A6C.LSPWRSJOYWSJSGML.VQLYSPLUN.DEPLUG.MXPLUGPLRXNSTGNOVANEXILXEHLTUMLLY.MXLLY.DELLY.BALLYLILY34.SAELCI34.SAELAA.DEEL.MXELCTLT0R0V.L0Q1G.L0JVB.L0JTM.LFDMT0IJU.L- Published at
- by globenewswire.com
mixedmixedWet-Age Related Macular Degeneration Market to Observe Stupendous Growth by 2032, Predicts DelveInsight | Key Players - AbbVie, Opthea, AffaMed Therapeutics, EyeBiotech, Novartis, Hoffmann-La Roche, K
The increasing number of diagnosed cases of wet AMD, the current therapies, and the launch of emerging therapies will drive the wet AMD market growth in...- Published at
- by prnewswire.com
mixedmixedAge-related macular degeneration (AMD) market size to increase by USD 4,360.68 million: Evolving Opportunities with Amgen Inc and Apellis Pharmaceuticals Inc among others - Technavio
/PRNewswire/ -- Technavio report provides the key offerings of 15+ vendors of the age-related macular degeneration market. For Instance, one of the key...